Half of all colorectal cancers bear KRAS-activating mutations that affect the metabolic dependencies of cancer cells and drive resistance to commonly used drugs. A new study provides insights into KRAS-driven metabolic rewiring and identifies a new therapeutic target for KRAS-mutant cancers.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fearon, E. R. & Vogelstein, B. Cell 61, 759–767 (1990).
The Cancer Genome Atlas Network. Nature 487, 330–337 (2012).
Schwitalla, S. et al. Cell 152, 25–38 (2013).
Haigis, K. M. et al. Nat. Genet. 40, 600–608 (2008).
Verissimo, C. S. et al. eLife 5, e18489 (2016).
Gimple, R. C. & Wang, X. Front. Oncol. 9, 965 (2019).
Kimmelman, A. C. Clin. Cancer Res. 21, 1828–1834 (2015).
Warburg, O. Science 123, 309–314 (1956).
Smith, B. et al. Cell Rep. 17, 821–836 (2016).
Ying, H. et al. Cell 149, 656–670 (2012).
Najumudeen, A. K. et al. Nat. Genet. https://doi.org/10.1038/s41588-020-00753-3 (2020).
Guinney, J. et al. Nat. Med. 21, 1350–1356 (2015).
Canon, J. et al. Nature 575, 217–223 (2019).
Hallin, J. et al. Cancer Discov. 10, 54–71 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Bootsma, S., van Neerven, S.M. & Vermeulen, L. Exploiting KRAS-mediated metabolic reprogramming as a therapeutic target. Nat Genet 53, 9–10 (2021). https://doi.org/10.1038/s41588-020-00758-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41588-020-00758-y
